Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Person › Details

Josh Bilenker (Loxo Oncology Inc. (Nasdaq: LOXO))

Bilenker, Josh (Loxo Oncology 201811 CEO)

 

Organisation Organisation Loxo Oncology Inc. (Nasdaq: LOXO)
Products Product Vitrakvi®
  Product 2 drug development
Document Source Bayer Corporation. (11/26/18). "Press Release: FDA Approves Vitrakvi (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion". Whippany, NJ & Stamford, CT.
     

   
Record changed: 2019-01-07

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px


More documents for Josh Bilenker


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px




» top